The Only Futures Trading Guide You’ll Ever Need
Regardless of your level of futures trading prowess, our Technical Analysis Guide has something to help you succeed in today’s futures markets.
Download your FREE Technical Analysis Trading Guide Today!
Jeffrey A. Meckler, insider at Indaptus Therapeutics
Jeffrey A. Meckler Insider Alerts

Get notified the next time Jeffrey A. Meckler buys or sells Indaptus Therapeutics stock. Enter your email address below to get our daily insider buying and selling report.

Jeffrey A. Meckler Insider Information

Jeffrey Meckler currently serves as our Chief Executive Officer, bringing more than 30 years of financial and healthcare leadership experience to the company. Most recently, Jeff was the CEO of Intec Pharma, and prior to that, CEO of Cocrystal Pharma, transforming it from a research company into a clinical and development company. Earlier in his career, Jeff was managing director of the Andra Group, a life sciences consulting firm, and acted as a director and interim CEO of Cypress Bioscience after its acquisition by Royalty Pharma. Jeff started his career at Pfizer, where he held a series of positions in manufacturing systems, market research, business development, strategic planning and corporate finance, which included playing a significant role in acquisitions and divestitures. He has also served as a director of QLT, Inc., Cocrystal Pharma, ClearFarma USA, Kyalin Bioscience, and Alveolus, and currently serves as director of Travere Therapeutics, where he also previously served as Chairman. Jeff is the past President and continues to serve on the Board of Children of Bellevue, a non-profit organization focused on advocating and developing pediatric programs at Bellevue Hospital Center. He holds a B.S. in industrial management, an M.S. in industrial administration from the Tepper School of Business at Carnegie Mellon University, and a J.D. from Fordham University’s School of Law.

What is Jeffrey A. Meckler's net worth?

The estimated net worth of Jeffrey A. Meckler is at least $1.03 million as of August 28th, 2019. Mr. Meckler owns 196,761 shares of Indaptus Therapeutics stock worth more than $1,025,125 as of December 4th. This net worth evaluation does not reflect any other assets that Mr. Meckler may own. Learn More.

How do I contact Jeffrey A. Meckler?

The corporate mailing address for Mr. Meckler and other Indaptus Therapeutics executives is 12 Hartom Street, Har Hotzvim, Jerusalem 777512. Indaptus Therapeutics can also be reached via phone at (646) 374-8050 and via email at [email protected]

Has Jeffrey A. Meckler been buying or selling shares of Indaptus Therapeutics?

During the last quarter, Jeffrey A. Meckler has bought $65,108.00 in Indaptus Therapeutics stock. Most recently, on Thursday, November 18th, Jeffrey A. Meckler bought 11,187 shares of Indaptus Therapeutics stock. The stock was acquired at an average cost of $5.82 per share, with a total value of $65,108.34.

Are insiders buying or selling shares of Indaptus Therapeutics?

In the last year, Indaptus Therapeutics insiders bought shares 1 times. They purchased a total of 11,187 shares worth more than $65,108.34. The most recent insider tranaction occured on November, 18th when CEO Jeffrey A Meckler bought 11,187 shares worth more than $65,108.34. Insiders at Indaptus Therapeutics own 3.3 % of the company.

Information on this page was last updated on 11/18/2021.

Jeffrey A. Meckler Insider Trading History at Indaptus Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/18/2021Buy11,187$5.82$65,108.34View SEC Filing Icon  
See Full Table

Jeffrey A. Meckler Buying and Selling Activity at Indaptus Therapeutics

This chart shows Jeffrey A Meckler's buying and selling at Indaptus Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Indaptus Therapeutics Company Overview

Indaptus Therapeutics logo
Indaptus Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on research and development and clinical trials. The company develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing efficient gastric retention. The company was founded by Michael James Newman on February 24, 2021 and is headquartered in New York, NY.
Read More

Today's Range

Now: $5.21
Low: $4.88
High: $5.40

50 Day Range

MA: $7.37
Low: $5.21
High: $11.58

2 Week Range

Now: $5.21
Low: $4.88
High: $28.83

Volume

268,278 shs

Average Volume

211,463 shs

Market Capitalization

$42.67 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.89
Learn to Customize Your Own Options Trading Strategy
This guide will help you evaluate and analyze your trading plan to create a custom options trading strategy tailored to your risk profile and market outlook. Learn how to take your trading to the next level.
Download your FREE Options Strategy Guide Today!